2021, doi:10.3389/fendo.2021.721135 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)
Intranasal Administration: Some sources mention intranasal administration as another potential route
Solutions include increasing the dose (raising the entire curve including the trough), splitting the dose into twice-weekly injections (reducing the trough depth while maintaining the same total weekly dose), or switching to a medication with a longer half-life (semaglutide troughs are shallower than tirzepatide troughs due to its longer half-life)
Simultaneously, optimized folding conditions ensure correct disulfide bond pairing, guaranteeing product activity
States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all
J Gastro Hepatol